Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572

British Journal of Clinical Pharmacology

Volumn 72, Issue 1, 2011, Pages 103-108

  Song, Ivy ^a   Borland, Julie ^a   Chen, Shuguang ^a   Lou, Yu ^a   Peppercorn, Amanda ^a   Wajima, Toshihiro ^b   Min, Sherene ^a   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Atazanavir; Drug interaction; HIV integrase; Ritonavir; S GSK1349572

Indexed keywords

ATAZANAVIR; GSK 1349572; INTEGRASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EYE JAUNDICE; HUMAN; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; GLUCURONOSYLTRANSFERASE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; YOUNG ADULT;

EID: 79958719816     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03947.x     Document Type: Article

References (12)

1. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52: 350-6.
2. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605-12.
3. Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P. Raltegravir versus efavirenz regimens in treatment-naïve HIV-1 infected patients: 96 weeks efficacy, durability, subgroup, safety, and metabolic analysis. J Acquir Immune Defic Syndr 2010; 55: 39-48.
4. McColl DJ, Fransen S, Gupta S, Parking N, Margot N, Chuck S, Cheng A, Miller M. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase 2 study of elvitegravir (GS-9137) [Abstract 9]. XVI International HIV Drug Resistance Workshop. Antivir Ther 2007; 12: 11.
5. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC. Pharmacokinetics and safety in healthy subjects of S/GSK1349572, a next generation HIV integrase inhibitor in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 254-8.
6. Song I, Chen S, Lou Y, Borland J, Fujiwara T, Piscitelli S, Min S. Pharmacokinetic and pharmacodynamic relationship of S/GSK1349572, a next generation integrase inhibitor, in HIV-1 infected patients. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Abstract WEPEB250.
7. Lalezari J, Sloan L, DeJesus E, Hawkins T, Mccurdy L, Song I, Borland J, Stroder R, Chen S, Lou Y, Underwood M, Fujiwara T, Piscitelli S, Min S. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naïve HIV-1-infected patients. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
8. Sato A, Kobayashi M, Yoshinaga T, Fujiwara T, Underwood M, Johns B, Foster S, Hazen R, Ferris R, Brown K, Garvey E. S/GSK1349572 is a potent next generation HIV integrase inhibitor. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Abstract WEPEA097.
9. Reyataz [Package Insert]. Princeton, NJ: Bristol Myers Squibb, 2010.
10. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048-59.
11. Rockstroh J, Felizarta F, Maggiolo F, Pulido F, Stellbrink HJ, Tsybakova O, Yeni P, Almond S, Brothers C, Song I, Min S. Once-daily S/GSK1349572 combination therapy in antiretroviral-naive adults: rapid and potent 24-week antiviral response in SPRING-1 (ING11276). Tenth International Congress on Drug Therapy in HIV Infection. November 7-11, 2010. Glasgow. Abstract O434.
12. Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F, Maggiolo F, De Luca A, Paraninfo G, Antonucci F, Migliorino G, Lazzarin A, Di Perri G, Rizzardini G, Esposito R, Carosi G. Hyperbilirubinemia during atazanavir treatment in 2, 404 patients in the Italian expanded access program and MASTER cohorts. Infection 2009; 37: 244-9.